Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | BL-B01D1 |
| Trade Name | |
| Synonyms | BL B01D1|BLB01D1|BMS986507|BMS 986507|BMS-986507|Izalontamab brengitecan |
| Drug Descriptions |
BL-B01D1 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting EGFR and ERBB3 (HER3) linked to a topoisomerase I inhibitor, which potentially decreases tumor growth (PMID: 38823410). |
| DrugClasses | EGFR Antibody 72 HER3 (ERBB3) Antibody 28 |
| CAS Registry Number | 2760528-47-8 |
| NCIT ID | C186670 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BL-B01D1 | BL-B01D1 | 0 | 4 |
| BL-B01D1 + Nivolumab | BL-B01D1 Nivolumab | 0 | 1 |
| BL-B01D1 + Osimertinib | BL-B01D1 Osimertinib | 0 | 1 |
| BL-B01D1 + Pembrolizumab | BL-B01D1 Pembrolizumab | 0 | 1 |